- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: September 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in September 2027, from ClinicalTrials.gov.
Trial readouts
193 trials: 82 phase 3 (including phase 2/3) and 111 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Sep 2027 | AbbVie | Armour Thyroid, LevothyroxineA Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adu… | Hypothyroidism | Phase 2/3 | Active not recruiting | NCT06345339 |
| Sep 2027 | AbbVie | UpadacitinibA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Co… | Crohn's Disease | Phase 3 | Active not recruiting | NCT03345823 |
| Sep 2027 | Alkermes | OLZ/SAMLong-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | Bipolar I Disorder, Schizophrenia | Phase 3 | Enrolling by invitation | NCT04987229 |
| Sep 2027 | Alvogen Korea | AK-D101A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD | Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder and 1 more | Phase 3 | Not yet recruiting | NCT07678827 |
| Sep 2027 | Applied Biologics, LLC | BIOxHEAL (human amniotic membrane allograft)a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Singl… | Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft and 1 more | Phase 3 | Recruiting | NCT07852338 |
| Sep 2027 | Birch BioMed Inc | IP1 control cream (Vehicle base), IP2 - 0.5% w/w FS2Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients | Burn Scar, Burn Wound | Phase 2/3 | Recruiting | NCT06807021 |
| Sep 2027 | Castle Creek Biosciences, LLC. | D-FiEvaluation of D-Fi for the Treatment of Wounds Due to DEB | Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | NCT06892639 |
| Sep 2027 | Sino Biopharmaceutical Limited | TQB2102 for injection, Trastuzumab injection and Pertuzumab Injection and Docetax…A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Can… | HER2-positive Breast Cancer | Phase 3 | Recruiting | NCT07043725 |
| Sep 2027 | Sino Biopharmaceutical Limited | TQH3906 capsules, Deucravacitinib tablets 6 mgA Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Psoriasis | Phase 3 | Recruiting | NCT07724366 |
| Sep 2027 | Cytokinetics | Omecamtiv Mecarbil (OM)Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 3 | Recruiting | NCT06736574 |
| Sep 2027 | Definium Therapeutics | DT120A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | Major Depressive Disorder | Phase 3 | Recruiting | NCT07592689 |
| Sep 2027 | Dompé Farmaceutici S.p.A | CenegerminEfficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | Non-Arteritic Anterior Ischemic Optic Neuropathy | Phase 3 | Recruiting | NCT07453888 |
| Sep 2027 | Dr. Falk Pharma GmbH | norucholic acidStudy with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | Phase 3 | Not yet recruiting | NCT06886360 |
| Sep 2027 | Eli Lilly and Company | OrforglipronA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | Hypertension | Phase 3 | Active not recruiting | NCT06952530 |
| Sep 2027 | Eli Lilly and Company | RetatrutideA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Obesity, Overweight and 1 more | Phase 3 | Active not recruiting | NCT07035093 |
| Sep 2027 | Eli Lilly and Company | OrforglipronA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | Hypertension, Overweight or Obesity | Phase 3 | Active not recruiting | NCT06948435 |
| Sep 2027 | Eli Lilly and Company | OrforglipronA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | Hypertension | Phase 3 | Active not recruiting | NCT06948422 |
| Sep 2027 | Gan & Lee Pharmaceuticals Co., Ltd. | GZR18 injectionExtension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Overweight or Obesity | Phase 3 | Recruiting | NCT07292441 |
| Sep 2027 | Genmab A/s | Rina-S, Paclitaxel, Topotecan and 2 moreAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant O… | Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | NCT07604766 |
| Sep 2027 | Jiangsu Hengrui Medicine | HR-1703A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma | Asthma With Eosinophilic Phenotype | Phase 3 | Active not recruiting | NCT06653322 |
| Sep 2027 | IDB VisionCare SDN BHD | Low dose atropine sulfate eye dropsAtropine in the Treatment of Myopia Study in Malaysia | Myopia Progression | Phase 3 | Recruiting | NCT07329777 |
| Sep 2027 | Joincare Pharmaceutical Group Industry Co., Ltd | JKN2401 InjectionA Phase 3 Trial of JKN2401 Injection in COPD | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Not yet recruiting | NCT07330310 |
| Sep 2027 | Kardigan, Inc. | danicamtivA Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy | Phase 2/3 | Recruiting | NCT07210723 |
| Sep 2027 | Keymed Biosciences Co.Ltd | CM336 InjectionStudy of CM336 in Relapsed or Refractory Multiple Myeloma Patients | Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | NCT07181239 |
| Sep 2027 | Kyverna Therapeutics, Inc. | Standard lymphodepletion regimen, KYV-101KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized Myasthenia Gravis | Phase 2/3 | Recruiting | NCT06193889 |
| Sep 2027 | ML Bio Solutions, Inc. | BBP-418 (ribitol)Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Phase 3 | Active not recruiting | NCT05775848 |
| Sep 2027 | Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW2821, Toripalimab, Gemcitabine and 1 more9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | Urothelial Carcinoma | Phase 3 | Recruiting | NCT06592326 |
| Sep 2027 | Otsuka Pharmaceutical | OPC-34712FUM/ Brexpiprazole fumarateTrial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Acute Schizophrenia | Phase 3 | Recruiting | NCT05325645 |
| Sep 2027 | Pharmazz, Inc. | Normal Saline, SovateltideAssess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | Acute Ischemic Stroke, Cerebral Stroke | Phase 3 | Recruiting | NCT05691244 |
| Sep 2027 | Shanghai Minwei Biotechnology Co., Ltd | MWN109 1, MWN109 2, MWN109 3Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity | Overweight , Obesity | Phase 3 | Not yet recruiting | NCT07778693 |
| Sep 2027 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 611Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) | Dermatitis, Atopic | Phase 3 | Recruiting | NCT07767253 |
| Sep 2027 | Ultragenyx Pharmaceutical Inc. | DTX301, Oral Corticosteroids, Sodium AcetateClinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency | OTC Deficiency | Phase 3 | Active not recruiting | NCT05345171 |
| Sep 2027 | X4 Pharmaceuticals, Inc | MavorixaforA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are … | Neutropenia | Phase 3 | Recruiting | NCT06056297 |
| Sep 2027 | Argenx SE | Efgartigimod PH20 SCA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | Phase 2/3 | Recruiting | NCT06392386 |
| Sep 2027 | Argenx SE | empasiprubart, IVIgA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP and 1 more | Phase 3 | Recruiting | NCT06920004 |
| Sep 1, 2027 | AstraZeneca | Dato-DXd, Durvalumab, Capecitabine and 1 moreA Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… | Breast Cancer | Phase 3 | Active not recruiting | NCT05629585 |
| Sep 1, 2027 | Lee's Pharmaceutical Limited | Socazolimab+cisplatin/carboplatin+paclitaxel+BevacizumabPhase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | Cervical Cancer | Phase 3 | Recruiting | NCT06459687 |
| Sep 1, 2027 | Novo | Cagrilintide, SemaglutideREDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | Cardiovascular Disease | Phase 3 | Active not recruiting | NCT05669755 |
| Sep 1, 2027 | Qilu Pharmaceutical Co., Ltd. | QL1706, Bevacizumab, Oxaliplatin injection and 2 moreA Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carci… | Hepatocellular Carcinoma | Phase 2/3 | Not yet recruiting | NCT05976568 |
| Sep 7, 2027 | Bristol-Myers Squibb | KarXTOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's D… | Psychosis Associated With Alzheimer's Disease | Phase 3 | Recruiting | NCT05980949 |
| Sep 10, 2027 | Sanofi | PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine and 7 moreStudy of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healt… | Pneumococcal Immunization | Phase 3 | Active not recruiting | NCT06824181 |
| Sep 12, 2027 | Bristol-Myers Squibb | BMS-986365, Enzalutamide, Abiraterone and 2 moreA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castrat… | Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | NCT06764485 |
| Sep 13, 2027 | Takeda Pharmaceutical Company | Vedolizumab IVA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | Crohn's Disease (CD) | Phase 3 | Recruiting | NCT04779320 |
| Sep 15, 2027 | Shanghai Bovax Biotechnology Co., Ltd. | 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,4…, GARDASIL®Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | Cervical Cancer, Vulvar Cancer and 12 more | Phase 3 | Recruiting | NCT04422366 |
| Sep 15, 2027 | Sinovac Biotech | Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 …, Hepatitis A vaccine (inactivated, adsorbed)Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine | Hepatitis A Vaccine | Phase 3 | Recruiting | NCT07793227 |
| Sep 19, 2027 | Paradigm Therapeutics | SD-101 Dermal Cream (6%)An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | Epidermolysis Bullosa (EB) | Phase 3 | Not yet recruiting | NCT07482813 |
| Sep 20, 2027 | Jiangsu Hengrui Medicine | SHR-A1904, Paclitaxel, Docetaxel, IrinotecanSHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or… | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | NCT06649292 |
| Sep 21, 2027 | Novartis | ianalumab s.c. q4w, ianalumab s.c. q12wSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Lupus Nephritis | Phase 3 | Active not recruiting | NCT05126277 |
| Sep 21, 2027 | Pfizer | MET097Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | Obesity and Overweight | Phase 3 | Active not recruiting | NCT07311850 |
| Sep 22, 2027 | Shanghai Kechow Pharma, Inc. | tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or da…Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | Melanoma | Phase 3 | Recruiting | NCT06008106 |
| Sep 23, 2027 | Roche Holding | NXT007, Human Coagulation Factor VIIIA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | Hemophilia A | Phase 3 | Recruiting | NCT07416526 |
| Sep 24, 2027 | Amgen | TarlatamabPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Small Cell Lung Cancer | Phase 3 | Recruiting | NCT07778316 |
| Sep 24, 2027 | Biogen | NusinersenA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (… | Spinal Muscular Atrophy | Phase 3 | Active not recruiting | NCT05067790 |
| Sep 24, 2027 | Merck & Co. | Zilovertamab vedotin, Rituximab, Gemcitabine and 3 moreA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C… | DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2/3 | Recruiting | NCT05139017 |
| Sep 24, 2027 | Takeda Pharmaceutical Company | Vedolizumab IVEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Phase 3 | Active not recruiting | NCT03221036 |
| Sep 24, 2027 | The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 Injection 2.0 mg, UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mgPhase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UN… | Type 2 Diabetes | Phase 3 | Recruiting | NCT07659574 |
| Sep 27, 2027 | Cellcolabs Clinical SPV Limited | Mesenchymal Stem Cells (MSC), Hyaluronic Acid (HA)An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal… | Knee Arthritis Osteoarthritis | Phase 2/3 | Recruiting | NCT07542808 |
| Sep 28, 2027 | Incyte | INCA034176, CorticosteroidsA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | Phase 3 | Recruiting | NCT06585774 |
| Sep 28, 2027 | Johnson & Johnson | Nipocalimab, EfgartigimodComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | Myasthenia Gravis | Phase 3 | Recruiting | NCT07217587 |
| Sep 28, 2027 | Merck & Co. | Bomedemstat, HydroxyureaBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | Essential Thrombocythemia | Phase 3 | Active not recruiting | NCT06456346 |
| Sep 28, 2027 | Pfizer | ibuzatrelvir, remdesivirA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | COVID-19 Infection | Phase 3 | Recruiting | NCT07013474 |
| Sep 28, 2027 | Regeneron Pharmaceuticals | fianlimab, cemiplimabA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced… | Advanced Non-Small Cell Lung Cancer | Phase 2/3 | Active not recruiting | NCT05785767 |
| Sep 29, 2027 | Johnson & Johnson | UstekinumabA Long-term Extension Study of Ustekinumab in Pediatric Participants | Crohn Disease, Colitis, Ulcerative and 1 more | Phase 3 | Active not recruiting | NCT05092269 |
| Sep 29, 2027 | The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mgUBT251 Injection Phase Ⅲ Study (Overweight or Obesity) | Obesity & Overweight | Phase 3 | Not yet recruiting | NCT07648225 |
| Sep 30, 2027 | AstraZeneca | Saruparib, Abiraterone Acetate, Darolutamide and 1 moreSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Active not recruiting | NCT06120491 |
| Sep 30, 2027 | Avecho Biotechnology | Cannabidiol (CBD) Capsule 75mgEvaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia | Insomnia | Phase 3 | Active not recruiting | NCT05840822 |
| Sep 30, 2027 | Biomed Industries, Inc. | BionetideTo Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | Rett Syndrome | Phase 3 | Recruiting | NCT06840496 |
| Sep 30, 2027 | Bisirna Therapeutics (Suzhou) Co., Ltd. | VSA012, Eculizumab (Soliris®)A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Partic… | Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Not yet recruiting | NCT07816237 |
| Sep 30, 2027 | CSPC Pharmaceutical Group | SYS6010 injection, Enlonstobart injection, Tislelizumab injection and 1 moreSYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Me… | Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | NCT07633873 |
| Sep 30, 2027 | CSPC Pharmaceutical Group | rhTNK-tPAPhase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. | Acute Ischemic Stroke | Phase 3 | Recruiting | NCT07201688 |
| Sep 30, 2027 | Centessa Pharmaceuticals plc | cleminorextonA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hyperso… | Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2/3 | Recruiting | NCT07598708 |
| Sep 30, 2027 | Chong Kun Dang | CKD-843 dose#1, CKD-843 dose#2, Dutasteride CapsulesA Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia | Androgenetic Alopecia | Phase 3 | Recruiting | NCT06916793 |
| Sep 30, 2027 | Grifols | Alpha-1 15%, Liquid Alpha1-PIA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Correspondin… | Alpha 1 Antitrypsin Deficiency | Phase 3 | Recruiting | NCT07555483 |
| Sep 30, 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Dry Powder Inhaler Simulant, HSK39004 Dry Powder Inhaler-0.75mgA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment … | COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Recruiting | NCT07583849 |
| Sep 30, 2027 | Inventiva S.A. | IVA337A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and F… | NASH - Nonalcoholic Steatohepatitis | Phase 3 | Active not recruiting | NCT04849728 |
| Sep 30, 2027 | Ono Pharmaceutical | ONO-4059ONO-4059 Study in Patients With Steroid-resistant Pemphigus | Pemphigus, Steroid-resistant Pemphigus | Phase 3 | Active not recruiting | NCT06696716 |
| Sep 30, 2027 | Sanofi | Amlitelimab, Topical corticosteroids, Topical tacrolimus or pimecrolimusA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 1… | Dermatitis Atopic | Phase 3 | Active not recruiting | NCT06241118 |
| Sep 30, 2027 | Shanghai RAAS Blood Products Co., Ltd. | SR604A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia | Hemophilia A, Hemophilia A and B and 1 more | Phase 3 | Not yet recruiting | NCT07876674 |
| Sep 30, 2027 | Shanghai Zhimeng Biopharma, Inc. | Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg groupA Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | ALS (Amyotrophic Lateral Sclerosis) | Phase 2/3 | Recruiting | NCT07082192 |
| Sep 30, 2027 | Tetra Discovery Partners | Zatolmilast/ BPN14770An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | Fragile X Syndrome | Phase 3 | Active not recruiting | NCT05367960 |
| Sep 30, 2027 | Vanda Pharmaceuticals Inc. | TradipitantMotion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | Motion Sickness | Phase 3 | Active not recruiting | NCT06138613 |
| Sep 30, 2027 | Vertex Pharmaceuticals | ELX/TEZ/IVA, IVAEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | Cystic Fibrosis | Phase 3 | Active not recruiting | NCT06460506 |
| Sep 2027 | AbbVie | IcalcaprantA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Major Depressive Disorder | Phase 2 | Recruiting | NCT07276997 |
| Sep 2027 | AbbVie | Lutikizumab, AdalimumabA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant… | Ulcerative Colitis | Phase 2 | Active not recruiting | NCT06257875 |
| Sep 2027 | Agenus | Botensilimab, BalstilimabA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | NCT05608044 |
| Sep 2027 | Alto Neuroscience, Inc. | ALTO-100ALTO-100 in Bipolar Disorder With Depression (BD-D) | Bipolar Disorder I or II With a Major Depressive Episode | Phase 2 | Recruiting | NCT06656416 |
| Sep 2027 | Antev Ltd. | Teverelix DP 180 mgA Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) A… | Advanced Prostate Cancer, GnRH Antagonist | Phase 2 | Not yet recruiting | NCT07457164 |
| Sep 2027 | Ascendis Pharma A/S | NavepegritideA Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | Achondroplasia | Phase 2 | Active not recruiting | NCT06732895 |
| Sep 2027 | Bilix Co.,Ltd. | BX-001N Experimental group 1, BX-001N Experimental group 2A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adve… | Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury | Phase 2 | Recruiting | NCT07164833 |
| Sep 2027 | Boryung Pharmaceutical Co., Ltd | BR101801A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | NCT07180771 |
| Sep 2027 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg and 1 morePhase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have… | Rheumatoid Arthritis | Phase 2 | Recruiting | NCT07423533 |
| Sep 2027 | Chaser Therapeutics, Inc. | PBSS1113PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1/2 | Recruiting | NCT07761533 |
| Sep 2027 | Sino Biopharmaceutical Limited | TQB3473 TabletsA Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adu… | Primary Immune Thrombocytopenia | Phase 2 | Not yet recruiting | NCT07083739 |
| Sep 2027 | Climb Bio, Inc. | BudoprutugA Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erthematosus | Phase 1/2 | Recruiting | NCT07564596 |
| Sep 2027 | Coherus Oncology, Inc. | Casdozokitug, Toripalimab, BevacizumabA Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metast… | Hepatocellular Carcinoma | Phase 2 | Active not recruiting | NCT06679985 |
| Sep 2027 | CorFlow Therapeutics AG | Therapeutic sequence, Diagnostic sequenceRandomised EValuation of Therapies for microvAscuLar Injury in STEACS | STEMI (ST Elevation MI) | Phase 2 | Not yet recruiting | NCT06935383 |
| Sep 2027 | Corcept Therapeutics | Relacorilant, Nab-paclitaxel, GemcitabineRelacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | Recruiting | NCT07259317 |
| Sep 2027 | Dizal Pharmaceuticals | DZD8586DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | NCT06539182 |
| Sep 2027 | Domain Therapeutics Australia Pty Ltd | DT-7012, Immune checkpoint inhibitorStudy of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06819735 |
| Sep 2027 | Eisbach Bio GmbH | EIS-12656, Olaparib, Trastuzumab deruxtecanEIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Advanced Solid Tumor, Homologous Recombination Deficiency and 1 more | Phase 1/2 | Recruiting | NCT06525298 |
| Sep 2027 | Elevar Therapeutics | LirafugratinibA Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult | Phase 2 | Recruiting | NCT07359820 |
| Sep 2027 | Eli Lilly and Company | LY3305677, LY3841136, Tirzepatide and 2 moreA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Obesity, Overweight | Phase 2 | Recruiting | NCT06143956 |
| Sep 2027 | Eli Lilly and Company | Macupatide, EloralintideA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Ov… | Overweight, Obesity | Phase 2 | Recruiting | NCT07589608 |
| Sep 2027 | Eli Lilly and Company | LY3537031A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | Irritable Bowel Syndrome, Diarrhea | Phase 2 | Recruiting | NCT07545759 |
| Sep 2027 | Genmab A/s | Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and… and 3 moreTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NH… | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma and 4 more | Phase 1/2 | Active not recruiting | NCT04542824 |
| Sep 2027 | Grünenthal GmbH | GRT7040, Hydrocodone bitartrate/ acetaminophen (HB/APAP)A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy | Acute Pain, Bunionectomy | Phase 2 | Not yet recruiting | NCT07807644 |
| Sep 2027 | Jiangsu Hengrui Medicine | SHR-2173 injectionA Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis | Generalized Myasthenia Gravis | Phase 2 | Not yet recruiting | NCT07622342 |
| Sep 2027 | HB BioTech, LLC | HB-1Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder | PTSD, Mental Illness | Phase 2 | Recruiting | NCT07499440 |
| Sep 2027 | Immatics Biotechnologies GmbH | IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy and 3 moreIMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | Refractory Cancer, Recurrent Cancer and 2 more | Phase 1/2 | Recruiting | NCT05958121 |
| Sep 2027 | Immunovant, Inc. | IMVT-1402A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Art… | Rheumatoid Arthritis | Phase 2 | Active not recruiting | NCT06754462 |
| Sep 2027 | Ionis Pharmaceuticals Inc | ION440, Sham procedureATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Partici… | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Phase 1/2 | Recruiting | NCT06430385 |
| Sep 2027 | Ionis Pharmaceuticals Inc | ION775A Study to Assess the Safety, Tolerability and Efficacy of ION775 | Hypertriglyceridemia, Severe Hypertriglyceridemia | Phase 2 | Recruiting | NCT07604974 |
| Sep 2027 | Iovance Biotherapeutics | IOV-4001A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or … | Unresectable Melanoma, Metastatic Melanoma and 2 more | Phase 1/2 | Recruiting | NCT05361174 |
| Sep 2027 | Jiangsu Hengrui Medicine | HRS-4508 tabletA Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Solid Tumor | Phase 2 | Recruiting | NCT07003321 |
| Sep 2027 | Kenai Therapeutics | RNDP-001, Syringe Front-Loading DeviceA Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease | Idiopathic Parkinson´s Disease, Parkinson's Disease | Phase 1/2 | Active not recruiting | NCT07106021 |
| Sep 2027 | MRM Health NV | Low-dose MH002, High-dose MH002Confirmatory Clinical Study in Active Ulcerative Colitis | Colitis, Ulcerative | Phase 2 | Recruiting | NCT07296315 |
| Sep 2027 | Marengo Therapeutics, Inc. | STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid T… | Advanced Solid Tumors, Genital Neoplasm, Female and 12 more | Phase 1/2 | Recruiting | NCT05592626 |
| Sep 2027 | Monument Therapeutics Limited | MT1988 Low Dose, MT1988 High DoseA Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Phase 1/2 | Recruiting | NCT07226895 |
| Sep 2027 | Navigator Medicines, Inc. | NAV-240A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | NCT07384975 |
| Sep 2027 | Newish Biotech (Wuxi) Co., Ltd. | NWRD09Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection | Persistent HPV16 Infection | Phase 1/2 | Not yet recruiting | NCT07536282 |
| Sep 2027 | NovelMed Therapeutics | NM8074Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NCT05731050 |
| Sep 2027 | Olix Pharmaceuticals, Inc. | OLX72021A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia | Androgenetic Alopecia (AGA) | Phase 1/2 | Recruiting | NCT07327359 |
| Sep 2027 | Oncodesign Precision Medicine | OPM-101Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 | Advanced Melanoma | Phase 1/2 | Not yet recruiting | NCT07040436 |
| Sep 2027 | Qilu Pharmaceutical Co., Ltd. | QLS12010A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | Phase 2 | Not yet recruiting | NCT07344051 |
| Sep 2027 | Shanghai Novamab Biopharmaceuticals Co., Ltd. | LQ036Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma | Asthma | Phase 2 | Recruiting | NCT07589439 |
| Sep 2027 | Shanghai Zhimeng Biopharma, Inc. | Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 20mg groupA Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy | Focal Epilepsy | Phase 2 | Recruiting | NCT06612775 |
| Sep 2027 | Sichuan Honghe Biotechnology Co., Ltd. | KH617+TMZ, KH617, TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16Phase 2 Clinical Trial of KH617 | Recurrent Glioblastoma | Phase 2 | Not yet recruiting | NCT07138001 |
| Sep 2027 | Sinocelltech Ltd. | SCTC21CA Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases | IgA Nephropathy | Phase 1/2 | Not yet recruiting | NCT06774664 |
| Sep 2027 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | STSP-0902 injectionA Study to Evaluate the Safety and Efficacy of Multiple Dose of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermia. | Oligozoospermia and/or Asthenozoospermia | Phase 2 | Not yet recruiting | NCT07833943 |
| Sep 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG006, ZG005ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | Small Cell Lung Cancer, Neuroendocrine Carcinoma | Phase 1/2 | Recruiting | NCT07038096 |
| Sep 2027 | Syndeio Biosciences, Inc | ZelquistinelZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Major Depressive Disorder | Phase 2 | Recruiting | NCT06547489 |
| Sep 2027 | TenNor Therapeutics (Zhongshan) Limited | TNP-2092 for injection, Vancomycin Hydrochloride for Injection, Oral antibiotics and 1 moreA Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants | Prosthetic Joint Infection (PJI) | Phase 2 | Not yet recruiting | NCT07858916 |
| Sep 2027 | Trace Neuroscience, Inc. | TRCN-1023FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | Amyotrophic Lateral Sclerosis | Phase 1/2 | Recruiting | NCT07674667 |
| Sep 2027 | Trevi Therapeutics, Inc. | NAL ERThe Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | Refractory Chronic Cough | Phase 2 | Recruiting | NCT07671924 |
| Sep 2027 | Upstream Bio, Inc. | VerekitugA Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | Severe Asthma | Phase 2 | Active not recruiting | NCT06966479 |
| Sep 2027 | Vensica Therapeutics Ltd. | NT 201 200U and Vibe System, NT 201 300U and Vibe SystemRELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bl… | Overactive Bladder (OAB) | Phase 2 | Recruiting | NCT07553065 |
| Sep 2027 | Wave Life Sciences | WVE-006A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | Alpha-1 Antitrypsin Deficiency | Phase 1/2 | Recruiting | NCT06405633 |
| Sep 2027 | iRegene Therapeutics Co., Ltd. | Human Dopaminergic Progenitor CellsThis Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic… | Parkinson Disease | Phase 1/2 | Recruiting | NCT07102342 |
| Sep 1, 2027 | Aeovian Pharmaceuticals, Inc. | AV078Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) | Tuberous Sclerosis Complex, Epilepsy | Phase 2 | Not yet recruiting | NCT07680322 |
| Sep 1, 2027 | Akeso | AK146D1 for injection, AK112 InjectionA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | Advanced Breast Cancer | Phase 2 | Recruiting | NCT07591090 |
| Sep 1, 2027 | Daiichi Sankyo | HER3-DXdA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Melanoma and 12 more | Phase 2 | Recruiting | NCT06172478 |
| Sep 1, 2027 | Gateway Institute for Brain Research | INS-GSHIntranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease | Parkinson Disease | Phase 2 | Recruiting | NCT05266417 |
| Sep 1, 2027 | Maxinovel Pty., Ltd. | MAX-40279, Azacitidine, VenetoclaxA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | Acute Myeloid Leukemia | Phase 2 | Recruiting | NCT07743112 |
| Sep 1, 2027 | Shanghai Vitalgen BioPharma Co., Ltd. | VGN-R08b 4.2×10^13 vg, VGN-R08b 8.4×10^13 vg, VGN-R08b 1.68×10^14 vgA Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations | Parkinson Disease (PD) | Phase 1/2 | Not yet recruiting | NCT07414290 |
| Sep 1, 2027 | Vigonvita Life Sciences | LV232 40mg, LV232 60mg, EscitalopramDose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD | MDD | Phase 2 | Recruiting | NCT06828887 |
| Sep 1, 2027 | Wockhardt | Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-ZidebactamThis is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam … | Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis | Phase 2 | Not yet recruiting | NCT07840105 |
| Sep 2, 2027 | Novartis | Asciminib Pediatric formulation group, Asciminib Adult formulation groupStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Myeloid Leukemia, Philadelphia Positive | Phase 1/2 | Recruiting | NCT04925479 |
| Sep 3, 2027 | Appello Pharmaceuticals, Inc. | AP-472A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With… | Parkinson Disease | Phase 2 | Recruiting | NCT07432958 |
| Sep 3, 2027 | Novo | NNC0662-0419, SemaglutideA Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | Recruiting | NCT07415954 |
| Sep 5, 2027 | Shenzhen Beike Bio-Technology Co., Ltd. | hUC-MSCs treatment (low dose), hUC-MSCs treatment (medium dose), hUC-MSCs treatment (high dose) and 1 moreTreatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells | Systemic Lupus Erythematosus (SLE) | Phase 1/2 | Recruiting | NCT07041801 |
| Sep 7, 2027 | Biothervax SpA | Vaccination with rBCG-N-RSV, Vaccination with conventional BCG (BCG-WT)rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older | Respiratory Syncytial Virus Infection Prevention, Tuberculosis Prevention | Phase 2 | Recruiting | NCT07762014 |
| Sep 9, 2027 | Novartis | PKN605A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | Atrial Fibrillation | Phase 2 | Recruiting | NCT07217067 |
| Sep 12, 2027 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | FXS6837 Dose 1, FXS6837 Dose 2FXS6837 for the Treatment of IgAN Patients | IgAN | Phase 2 | Not yet recruiting | NCT07502638 |
| Sep 13, 2027 | Sanofi | Isatuximab, Dexamethasone, Pomalidomide and 5 moreIsatuximab in Combination With Novel Agents in RRMM - Master Protocol | Plasma Cell Myeloma Refractory | Phase 1/2 | Recruiting | NCT04643002 |
| Sep 15, 2027 | Eccogene | ECC4703, ECC0509A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and i… | Metabolic Dysfunction-associated Steatohepatitis | Phase 2 | Recruiting | NCT07288138 |
| Sep 15, 2027 | Teva Pharmaceutical Industries Ltd. | TEV-56286A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy | Multiple System Atrophy | Phase 2 | Active not recruiting | NCT06568237 |
| Sep 16, 2027 | CSPC Pharmaceutical Group | SYH2070 injection dose1, SYH2070 injection dose2Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolem… | Diagnosed With HoFH | Phase 2 | Recruiting | NCT07591298 |
| Sep 17, 2027 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | NemtabrutinibA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | Lymphoma, B-Cell, Small Lymphocytic Lymphoma and 7 more | Phase 1/2 | Active not recruiting | NCT03162536 |
| Sep 17, 2027 | Arrowhead Pharmaceuticals | ARO-INHBE, TirzepatideA First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity | Phase 1/2 | Recruiting | NCT06700538 |
| Sep 18, 2027 | Chipscreen Biosciences, Ltd. | CS32582 capsule（low dose）, CS32582 capsule（medium dose）, CS32582 capsule（high dose）A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Phase 1/2 | Recruiting | NCT07129382 |
| Sep 20, 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | A166A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | Her 2 Positive Breast Cancer | Phase 2 | Recruiting | NCT07299825 |
| Sep 22, 2027 | Genfleet Therapeutics (Shanghai) Inc. | GFH276A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | Cancer, PDAC and 2 more | Phase 1/2 | Not yet recruiting | NCT07198321 |
| Sep 22, 2027 | Sanofi | SAR445399A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | Phase 2 | Recruiting | NCT07225569 |
| Sep 23, 2027 | Incyte | INCA000585Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Immune Thrombocytopenia | Phase 2 | Recruiting | NCT07104565 |
| Sep 23, 2027 | Pentixapharm AG | [90Y]Y-PentixaTher[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients | CNS Lymphoma | Phase 1/2 | Recruiting | NCT06132737 |
| Sep 24, 2027 | Verona Pharma | Nebulized Ensifentrine Suspension; 3 mgA Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | NCT06559150 |
| Sep 26, 2027 | Sinocelltech Ltd. | SCTB39GPhase I/II Study of SCTB39G in Advanced Solid Tumours | Advanced Malignant Solid Tumor | Phase 1/2 | Not yet recruiting | NCT07077252 |
| Sep 28, 2027 | CSPC Pharmaceutical Group | SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3) and 2 moreA Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Not yet recruiting | NCT07796477 |
| Sep 29, 2027 | Acurx Pharmaceuticals, Inc. | IbezapolstatACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection | Clostridium Difficile Infection Recurrence | Phase 2 | Recruiting | NCT07513285 |
| Sep 29, 2027 | AstraZeneca | AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) and 3 moreA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | Breast Cancer, Biliary Tract Carcinoma and 3 more | Phase 1/2 | Recruiting | NCT05123482 |
| Sep 30, 2027 | Altimmune, Inc. | PemvidutideRESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Alcohol-associated Liver Disease | Phase 2 | Active not recruiting | NCT07009860 |
| Sep 30, 2027 | Antengene Biologics Limited | ATG-022, pembrolizumab/KEYTRUDA®, CAPOXA Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative… | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 1/2 | Recruiting | NCT07327229 |
| Sep 30, 2027 | Beijing Gene Key Life Technology Co., Ltd | GKL-006 Injection, TACEGKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 2 | Recruiting | NCT07209813 |
| Sep 30, 2027 | BioInvent International AB | BI-1206, Rituximab, AcalabrutinibA Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | Indolent B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Recruiting | NCT03571568 |
| Sep 30, 2027 | CSPC Pharmaceutical Group | SYH2069 InjectionEfficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. | Overweight or Obesity | Phase 2 | Not yet recruiting | NCT07803991 |
| Sep 30, 2027 | Genmab A/s | rituximab, cyclophosphamide, doxorubicin, vincristine, and…, rituximab and lenalidomide, rituximab and bendamustine and 7 moreSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1/2 | Active not recruiting | NCT04663347 |
| Sep 30, 2027 | Hangzhou Sumgen Biotech Co., Ltd. | SG2918To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | Phase 1/2 | Recruiting | NCT07454187 |
| Sep 30, 2027 | Hangzhou Sumgen Biotech Co., Ltd. | SG301 SC InjectionTo Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Phase 2 | Recruiting | NCT07447986 |
| Sep 30, 2027 | Incyte | Ruxolitinib, Capecitabine, RegorafenibAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Pancreatic Cancer, Colorectal Cancer (CRC) and 2 more | Phase 2 | Active not recruiting | NCT02955940 |
| Sep 30, 2027 | LEO Pharma | SpesolimabEffisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous… | Generalized Pustular Psoriasis | Phase 2 | Active not recruiting | NCT03886246 |
| Sep 30, 2027 | MAIA Biotechnology, Inc. | 6-Thio-2'-Deoxyguanosine, CemiplimabTHIO Sequenced With Cemiplimab in Advanced NSCLC | Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | NCT05208944 |
| Sep 30, 2027 | Miltenyi Biomedicine GmbH | MB-CART19.1MB-CART19.1 in Refractory SLE | SLE - Systemic Lupus Erythematosus | Phase 1/2 | Recruiting | NCT06189157 |
| Sep 30, 2027 | Mochida Medical USA, Inc. | dMD-002, ControldMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy | Prostate Cancer | Phase 1/2 | Not yet recruiting | NCT07564102 |
| Sep 30, 2027 | Multitude Therapeutics Inc. | AMT-676, 5-FU, Leucovorin and 4 moreA Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | Colorectal Cancer | Phase 2 | Recruiting | NCT07474727 |
| Sep 30, 2027 | PTC Therapeutics | PTC844Study of PTC844 in Participants With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Phase 2 | Not yet recruiting | NCT07779616 |
| Sep 30, 2027 | Pyrotech Therapeutics, Inc. | PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapyPTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Recruiting | NCT06244992 |
| Sep 30, 2027 | Rein Therapeutics, Inc. | LTI-03, Dry Powder InhalerA Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | NCT06968845 |
| Sep 30, 2027 | Remix Therapeutics | REM-422Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma and 1 more | Phase 1/2 | Recruiting | NCT06118086 |
| Sep 30, 2027 | Ribocure Pharmaceuticals AB | RBD1119RBD1119 in Coronary Artery Disease (CAD) | Stable Coronary Artery Disease | Phase 2 | Not yet recruiting | NCT07884136 |
| Sep 30, 2027 | Satellos Bioscience Inc. | SAT-3247An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SA… | Duchenne Muscular Dystrophy (DMD) | Phase 2 | Enrolling by invitation | NCT06867107 |
| Sep 30, 2027 | Shanghai YingLi Pharmaceutical Co. Ltd. | YL-13027, HY-0102, Gemcitabine and 1 moreYL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | Phase 1/2 | Not yet recruiting | NCT06662669 |
| Sep 30, 2027 | Unlimited Biotechnology LLC | AAV9-Follistatin gene therapy, VEGF PlasmidCALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy | Age-related Muscle Decline | Phase 1/2 | Recruiting | NCT07443826 |
| Sep 30, 2027 | Wayshine Biopharm, Inc. | WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose level BA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | Non Small Cell Lung Cancer | Phase 2 | Recruiting | NCT06868485 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.